LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.
OKYO Pharma Limited (OKYO.L) Regulatory Development of OK-101 for Dry Eye Indications
London and Boston, MA, 29 June 2021 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory
OKYO Pharma Limited (OKYO.L) Publication of a Prospectus
Prospectus Publication Announcement
OKYO Pharma Limited (OKYO.L) Positive Data in an Animal Model using OK-201
OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
OKYO Pharma Limited (OKYO.L) Appointment of Chief Scientific Officer
OKYO announces the appointment of Dr Rajkumar Patil as Chief Scientific Officer